Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Page 1
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.
Sezer Z, Pavel STI, Inal A, Yetiskin H, Kaplan B, Uygut MA, Aslan AF, Bayram A, Mazicioglu M, Kalin Unuvar G, Yuce ZT, Aydin G, Kaya RK, Ates I, Kara A, Ozdarendeli A. Sezer Z, et al. Among authors: kara a. Vaccines (Basel). 2024 Jan 29;12(2):140. doi: 10.3390/vaccines12020140. Vaccines (Basel). 2024. PMID: 38400124 Free PMC article.
Vaccine-induced immunity wanes over time and warrants booster doses. We investigated the long-term (32 weeks) immunogenicity and safety of a third, homologous, open-label booster dose of TURKOVAC, administered 12 weeks after completion of the primary series in a randomized …
Vaccine-induced immunity wanes over time and warrants booster doses. We investigated the long-term (32 weeks) immunogenicity and safe …
Rehospitalization indications of children hospitalized for COVID-19 infections after discharge: Should we suspect long COVID?
Cem E, Kıymet E, Böncüoğlu E, Şahinkaya Ş, Çelebi MY, Gülderen M, Kara AA, Özenen GG, Bayram N, Devrim İ. Cem E, et al. Among authors: kara aa. Turk J Pediatr. 2023;65(4):583-591. doi: 10.24953/turkjped.2022.829. Turk J Pediatr. 2023. PMID: 37661673 Free article.
CONCLUSIONS: The findings of acute COVID-19 infection are well characterized, but there is still limited data on its long-term outcomes. The majority of the study population that had no underlying disease were thought to have complications from the COVID-19 infection. ...
CONCLUSIONS: The findings of acute COVID-19 infection are well characterized, but there is still limited data on its long-term outcom …
Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency.
Taghizade N, Babayeva R, Kara A, Karakus IS, Catak MC, Bulutoglu A, Haskologlu ZS, Akay Haci I, Tunakan Dalgic C, Karabiber E, Bilgic Eltan S, Yorgun Altunbas M, Sefer AP, Sezer A, Kokcu Karadag SI, Arik E, Karali Z, Ozhan Kont A, Tuzer C, Karaman S, Mersin SS, Kasap N, Celik E, Kocacik Uygun DF, Aydemir S, Kiykim A, Aydogmus C, Ozek Yucel E, Celmeli F, Karatay E, Bozkurtlar E, Demir S, Metin A, Karaca NE, Kutukculer N, Aksu G, Guner SN, Keles S, Reisli I, Kendir Demirkol Y, Arikoglu T, Gulez N, Genel F, Kilic SS, Aytekin C, Keskin O, Yildiran A, Ozcan D, Altintas DU, Ardeniz FO, Dogu EF, Ikinciogullari KA, Karakoc-Aydiner E, Ozen A, Baris S. Taghizade N, et al. Among authors: kara a. J Allergy Clin Immunol. 2023 Dec;152(6):1634-1645. doi: 10.1016/j.jaci.2023.08.004. Epub 2023 Aug 16. J Allergy Clin Immunol. 2023. PMID: 37595759
OBJECTIVE: Our aim was to determine the comparative efficacy and long-term outcome of therapy with immunosuppressants, CTLA4-immunoglobulin (abatacept), and hematopoietic stem cell transplantation (HSCT) in a single-country multicenter cohort of 98 patients with a 5-year m …
OBJECTIVE: Our aim was to determine the comparative efficacy and long-term outcome of therapy with immunosuppressants, CTLA4-immunogl …
Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study.
Ates I, Batirel A, Aydin M, Karadag FY, Erden A, Kucuksahin O, Armagan B, Guven SC, Karakas O, Gokdemir S, Altunal LN, Buber AA, Gemcioglu E, Zengin O, Inan O, Sahiner ES, Korukluoglu G, Sezer Z, Ozdarendeli A, Omma A, Kara A. Ates I, et al. Among authors: kara a. Vaccines (Basel). 2023 Jul 12;11(7):1234. doi: 10.3390/vaccines11071234. Vaccines (Basel). 2023. PMID: 37515050 Free PMC article.
The immunogenicity of vaccines decreases over time, causing a need for booster doses. This study aimed to present the long-term (Day 84) immunogenicity results of the double-blind, randomized, controlled, phase II Hybrid COV-RAPEL TR Study (NCT04979949), in which the TURKO …
The immunogenicity of vaccines decreases over time, causing a need for booster doses. This study aimed to present the long-term (Day …
Effect of Bioabsorbable Poly (dl-Lactide ε-Caprolactone) on Healing of Experimentally Injured Acute Traumatic Middle Ear Mucosa Damage.
İlhan N, Kara A, Şahin E, Yılmaz MS, Güven M, Erdoğan M, Demir D. İlhan N, et al. Among authors: kara a. J Int Adv Otol. 2023 Jun;19(3):206-211. doi: 10.5152/iao.2023.22883. J Int Adv Otol. 2023. PMID: 37272637 Free PMC article.
CONCLUSION: It can be concluded that absorbable poly (dl-lactide epsilon-caprolactone) is nonototoxic and biocompatible with the rat's middle ear cavity by short-term evaluation....
CONCLUSION: It can be concluded that absorbable poly (dl-lactide epsilon-caprolactone) is nonototoxic and biocompatible with the rat's middl …
Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A, Batirel A, Aydin M, Yilmaz Karadag F, Erden A, Kucuksahin O, Armagan B, Güven SC, Karakas O, Gokdemir S, Altunal LN, Buber AA, Gemcioglu E, Zengin O, Inan O, Sahiner ES, Korukluoglu G, Sezer Z, Ozdarendeli A, Kara A, Ates I. Omma A, et al. Among authors: kara a. Hum Vaccin Immunother. 2022 Nov 30;18(6):2122503. doi: 10.1080/21645515.2022.2122503. Epub 2022 Oct 31. Hum Vaccin Immunother. 2022. PMID: 36315843 Free PMC article. Clinical Trial.
With the Hybrid COV-RAPEL TR study, after the primary vaccination consisting of two doses of inactivated vaccine, antibody titers decreased in the long term; however, higher antibody titers are achieved than the primary vaccination after the booster dose administered after …
With the Hybrid COV-RAPEL TR study, after the primary vaccination consisting of two doses of inactivated vaccine, antibody titers decreased …
Does the use of bioabsorbable mesh for hiatal hernia repair at the time of bariatric surgery reduce recurrence rates? A meta-analysis.
Clapp B, Kara AM, Nguyen-Lee PJ, Alvarado L, Marr JD, Annabi HM, Davis B, Ghanem OM. Clapp B, et al. Among authors: kara am. Surg Obes Relat Dis. 2022 Dec;18(12):1407-1415. doi: 10.1016/j.soard.2022.08.004. Epub 2022 Aug 10. Surg Obes Relat Dis. 2022. PMID: 36104252
BACKGROUND: Anywhere from 16% to 37% of patients undergoing bariatric and metabolic surgery are estimated to have a hiatal hernia. To address the lack of long-term data showing the efficacy of bioabsorbable mesh in reducing the recurrence of hiatal hernia in patients who u …
BACKGROUND: Anywhere from 16% to 37% of patients undergoing bariatric and metabolic surgery are estimated to have a hiatal hernia. To addres …
Does bioabsorbable mesh reduce hiatal hernia recurrence rates? A meta-analysis.
Clapp B, Kara AM, Nguyen-Lee PJ, Annabi HM, Alvarado L, Marr JD, Ghanem OM, Davis B. Clapp B, et al. Among authors: kara am. Surg Endosc. 2023 Mar;37(3):2295-2303. doi: 10.1007/s00464-022-09514-1. Epub 2022 Aug 11. Surg Endosc. 2023. PMID: 35951120
INTRODUCTION: The use of bioabsorbable mesh at the hiatus is controversial. Long-term data are scant. We evaluated the world literature and performed a meta-analysis to determine if these meshes were effective in reducing recurrence. ...CONCLUSIONS: Hiatal hernia repair wi …
INTRODUCTION: The use of bioabsorbable mesh at the hiatus is controversial. Long-term data are scant. We evaluated the world literatu …
Qualitative Analysis of Team Communication with a Clinical Texting System at a Midwestern Academic Hospital.
Lee JL, Kara A, Huffman M, Matthias MS, Radecki B, Savoy A, Schaffer JT, Weiner M. Lee JL, et al. Among authors: kara a. Appl Clin Inform. 2022 Mar;13(2):391-397. doi: 10.1055/s-0042-1744389. Epub 2022 Mar 16. Appl Clin Inform. 2022. PMID: 35294986 Free PMC article.
A lack of shared understanding regarding when and how to use texting may require long-term solutions that address teamwork and appropriateness....
A lack of shared understanding regarding when and how to use texting may require long-term solutions that address teamwork and approp …
Long Term Outcomes after Laparoscopic Assisted Trans-Gastric Endoscopic Retrograde Cholangiopancreatography.
Clapp B, Wicker E, Vivar A, Kara AM, Gamez J, Davis B. Clapp B, et al. Among authors: kara am. JSLS. 2021 Jul-Sep;25(3):e2021.00048. doi: 10.4293/JSLS.2021.00048. JSLS. 2021. PMID: 34552319 Free PMC article.
We evaluated these patients with at least a 3-year follow-up to determine long term outcomes. METHODS: We conducted a chart review of patients who underwent a t-ERCP with at least a 3-year follow-up. ...The most common pathology was benign biliary stricture (n = 6), follow …
We evaluated these patients with at least a 3-year follow-up to determine long term outcomes. METHODS: We conducted a chart review of …
46 results